Skip to content

PRP therapy

PRP therapy - PRPT

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030190219
Enrollment
20
Registered
2020-02-19
Start date
2017-07-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral nerve injury

Interventions

PRP is dispendide after peripheral blood aspiration and contrifuge. PRP is injected on repaire site of injured peripheral nerve.

Sponsors

Hara Yuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who injured peripheral nerve over 20 years old male and female Patients whose injury situation and injury site were revealed Patients who can completed all study schedule

Exclusion criteria

Exclusion criteria: The patients who had suffered infection.The diabetic patient who is under medication.The patient who have collagen disease. The patient who have bood system disorder. The patient who have anemia. The patient who have used anticoagulant. The patient who have used steroids within 3 months. The patient who has a doubt or diagnostic neoplastic lesion within 5 years before agreement. The patient who has not ability for agreement with own will. The patient who has not ability for agreement by the reading and writeing The patient who has been judged to be inappropriate as a subject by the doctor incharge.

Design outcomes

Primary

MeasureTime frame
Incidence of all adverse events that occurred during the clinical trials

Secondary

MeasureTime frame
Nerve regeneration( MMT, Semmes-Weinstein monofilament test,Tinel sign) Electromyography Evluation of PRP(Blood cell number, Concentlation of Growth factor)

Countries

Japan

Contacts

Public ContactHara Yuki

University of Tsukuba Hospital

yukihara@md.tsukuba.ac.jp+81-29-853-3219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026